Biomarkers of Maternal Mitochondrial Adaptation During Pregnancy

Abstract

Pregnancy induces profound metabolic and physiological adaptations in the maternal body, notably within mitochondrial function, to meet increased energy demands and support fetal development. The identification and monitoring of biomarkers indicative of maternal mitochondrial adaptation have gained prominence, offering clinicians valuable insights into maternal health, risk stratification, and possible complications. This review synthesizes recent scientific evidence on the epidemiology, pathophysiological mechanisms, risk factors, clinical implications, diagnostic modalities, management strategies, and emerging therapeutic and guideline perspectives regarding mitochondrial biomarkers during pregnancy. Clinically relevant insights are emphasized to bridge bench-to-bedside translation in maternal-fetal medicine.

Introduction

Mitochondria are central to cellular energy metabolism, redox homeostasis, and biosynthetic pathways. During pregnancy, the maternal body undergoes significant mitochondrial adaptation, characterized by changes in mitochondrial biogenesis, dynamics, and function to meet the heightened metabolic demands of gestation. Disruption in maternal mitochondrial adaptation is implicated in pregnancy complications such as preeclampsia, gestational diabetes mellitus (GDM), intrauterine growth restriction (IUGR), and preterm birth. The search for reliable biomarkers reflecting these mitochondrial changes is crucial for early detection, risk assessment, and targeted management of maternal-fetal disorders. Recent advances in high-throughput omics, metabolomics, and molecular diagnostics have expanded the array of candidate biomarkers, including mitochondrial DNA (mtDNA), oxidative stress markers, and proteins regulating mitochondrial dynamics.

Epidemiology / Disease Burden

Pregnancy-related complications linked to impaired mitochondrial adaptation are a significant cause of maternal and perinatal morbidity and mortality worldwide. Preeclampsia affects 5–8% of pregnancies globally, while gestational diabetes complicates approximately 7% of pregnancies, with both conditions showing associations with mitochondrial dysfunction. The burden is disproportionately higher in low- and middle-income countries due to limited access to advanced diagnostic and preventive healthcare. Recent population-based studies underscore the contribution of mitochondrial dysregulation to adverse outcomes, emphasizing the need for improved biomarker-driven risk stratification in antenatal care.

Pathophysiology

Maternal mitochondrial adaptation involves increased mitochondrial biogenesis, enhanced oxidative phosphorylation, and dynamic regulation of mitochondrial fusion and fission. These adaptations ensure adequate ATP production and support anabolic processes for fetal growth. Disrupted adaptation leads to excessive generation of reactive oxygen species (ROS), mitochondrial DNA damage, and impaired cellular signaling. Key molecular mediators include peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), nuclear respiratory factors (NRFs), and mitochondrial transcription factor A (TFAM). Inadequate adaptation may result in placental insufficiency, endothelial dysfunction, and altered maternal metabolic homeostasis, underlying the pathogenesis of preeclampsia, GDM, and fetal growth restriction.

Risk Factors

Several maternal factors predispose to impaired mitochondrial adaptation during pregnancy. Advanced maternal age, obesity, pre-existing metabolic syndrome, diabetes, hypertension, and genetic variants in mitochondrial genes increase vulnerability. Environmental insults such as smoking, exposure to toxins, and nutritional deficiencies (especially in B vitamins and antioxidants) further compromise mitochondrial health. Familial and ethnic predispositions have also been reported, highlighting the interplay between genetic susceptibility and environmental exposures in modulating mitochondrial function during gestation.

Clinical Features

Clinical manifestations of disrupted mitochondrial adaptation are often nonspecific but may present as excessive fatigue, myalgia, or exercise intolerance in pregnant women. More severe cases manifest as complications like preeclampsia, characterized by hypertension and proteinuria; gestational diabetes with hyperglycemia; or fetal growth restriction, evident on prenatal imaging. The detection of subclinical mitochondrial dysfunction is challenging, necessitating the use of sensitive and specific biomarkers to guide early clinical intervention before complications ensue.

Diagnosis

Biomarkers of maternal mitochondrial adaptation encompass a range of molecular, biochemical, and functional indicators. Circulating cell-free mitochondrial DNA (cf-mtDNA) is elevated in preeclampsia and correlates with disease severity. Measurement of oxidative stress markers, such as malondialdehyde (MDA) and 8-hydroxy-2-deoxyguanosine (8-OHdG), reflects mitochondrial ROS generation. Assessment of mitochondrial respiratory chain enzyme activities in peripheral blood mononuclear cells and quantification of proteins involved in mitochondrial dynamics (e.g., mitofusin-2, dynamin-related protein 1) offer mechanistic insight. Advanced metabolomic profiling identifies shifts in acylcarnitine profiles, lactate/pyruvate ratios, and other metabolites implicating mitochondrial bioenergetic adaptation. Integrating these biomarkers with clinical risk models enhances the prediction of adverse pregnancy outcomes.

Treatment & Management

There are currently no specific therapies targeting mitochondrial dysfunction in pregnancy; management remains supportive and focused on underlying complications. Antioxidant supplementation (e.g., vitamins C and E, coenzyme Q10) has been explored in clinical trials but with mixed results. Optimizing glycemic control in GDM, managing hypertension, and ensuring adequate maternal nutrition are essential. Lifestyle interventions, including moderate exercise and smoking cessation, may bolster mitochondrial resilience. Ongoing research is evaluating targeted therapies that enhance mitochondrial biogenesis or mitigate oxidative stress as potential adjuncts in high-risk pregnancies.

Recent Advances / Emerging Therapies

Recent technological advances in omics and single-cell analyses are refining the landscape of mitochondrial biomarker discovery. Next-generation sequencing enables sensitive detection of mtDNA mutations and heteroplasmy associated with pregnancy complications. Novel mitochondrial-targeted antioxidants, such as MitoQ and SS-31, are under investigation in preclinical and early-phase clinical studies for their ability to reduce oxidative damage and improve placental function. Proteomic approaches are identifying new signaling molecules involved in mitochondrial dynamics, offering potential for biomarker-guided personalized interventions. Furthermore, exosome-based delivery of mitochondrial modulators and gene editing technologies represent future avenues for therapeutic innovation.

Guideline Recommendations

Current clinical guidelines from leading organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the International Federation of Gynecology and Obstetrics (FIGO) do not yet endorse routine mitochondrial biomarker screening in pregnancy. However, they recognize the importance of early detection and management of complications associated with mitochondrial dysfunction. Consensus is emerging on the need for research-driven validation of mitochondrial biomarkers for risk stratification, particularly in women with preeclampsia, GDM, or previous adverse pregnancy outcomes. Multidisciplinary collaboration is advocated to integrate molecular diagnostics into routine antenatal care as evidence evolves.

Conclusion

Maternal mitochondrial adaptation is fundamental to a healthy pregnancy, and its disruption is implicated in a spectrum of obstetric complications. Advances in the identification and validation of mitochondrial biomarkers hold promise for improving early risk assessment and guiding individualized management strategies in maternal-fetal medicine. While clinical implementation awaits further research and guideline endorsement, awareness of these biomarkers and their pathophysiological underpinnings is essential for clinicians managing high-risk pregnancies. Ongoing translational research and multidisciplinary collaboration will shape the future of precision care in maternal health.